SynthesisPloS one2015
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204798 (Impact of Low-dose Dexmedetomidine on Outcomes of Elderly Admitted to ICU After Noncardiac Surgery), which is not on this map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Low-dose Dexmedetomidine on Outcomes of Elderly Admitted to ICU After Noncardiac Surgery: a Randomized Controlled Trial
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis.Sleep & breathing = Schlaf & Atmung · 2023Pooled it
- Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.Frontiers in psychiatry · 2022Pooled it
- Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review.European journal of clinical pharmacology · 2020Pooled it
- Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.European archives of psychiatry and clinical neuroscience · 2017Pooled it
- Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.Clinical and translational science · 2023Trial
- Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.Neuropsychopharmacology reports · 2019Trial
- Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial.PLoS medicine · 2018Trial
- Suvorexant for the treatment of sleep disorders in children with severe cerebral palsy.Sleep & breathing = Schlaf & Atmung · 2025Article
- A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells.Anatomy & cell biology · 2022Article
- Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.Neuropsychopharmacology reports · 2021Review
- Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant.Advances in therapy · 2021Article
- Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey.BMJ open · 2020Article
- Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.Neuroscience bulletin · 2020Review
- Effectiveness of Auricular Acupuncture for Insomnia: An Overview of Systematic Reviews.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews.Systematic reviews · 2019Review
- Effectiveness and safety of acupuncture for insomnia: Protocol for a systematic review.Medicine · 2019Article
- Hypocretin Mediates Sleep and Wake Disturbances in a Mouse Model of Traumatic Brain Injury.Journal of neurotrauma · 2019Article
- Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- Suvorexant for insomnia in older adults: a perspective review.Drugs in context · 2018Review
- Central and peripheral circadian clocks and their role in Alzheimer's disease.Disease models & mechanisms · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials evaluating suvorexant for primary insomnia.
methodsRelevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations through June 27, 2015. We performed a systematic review and meta-analysis of suvorexant trial efficacy and safety outcomes. The primary efficacy outcomes were either subjective total sleep time (sTST) or subjective time-to-sleep onset (sTSO) at 1 month. The secondary outcomes were other efficacy outcomes, discontinuation rate, and individual adverse events. The risk ratio, number-needed-to-treat/harm, and weighted mean difference (WMD) and 95% confidence intervals (CI) based on a random effects model were calculated.
resultsThe computerized literature database search initially yielded 48 results, from which 37 articles were excluded following a review of titles and abstracts and another eight review articles after full-text review. Thus, we identified 4 trials that included a total of 3,076 patients. Suvorexant was superior to placebo with regard to the two primary efficacy outcomes (sTST: WMD = -20.16, 95% CI = -25.01 to -15.30, 1889 patients, 3 trials, sTSO: WMD = -7.62, 95% CI = -11.03 to -4.21, 1889 patients, 3 trials) and was not different from placebo in trial discontinuations. Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/sedation, fatigue, dry mouth, and rebound insomnia.
conclusionsOur analysis of published trial results suggests that suvorexant is effective in treating primary insomnia and is well-tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.